Levosimendan in High Risk Heart Valve Surgery
Launched by KUOPIO UNIVERSITY HOSPITAL · Sep 8, 2005
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
200 patients are prospectively randomized in a double blind study investigating the efficacy of levosimendan in heart failure after cardiac surgery. Levosimendan/placebo is administered as 24 hour continuous infusion beginning after anesthesia induction. Primary endpoint being adrenergic inotrope need after cardiopulmonary bypass and secondary endpoints hospital and 6-month mortality and major organ failure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Eligible for cardiac valve or combined CABG and cardiac valve surgery:
- • Clinical signs of cardiac insufficiency
- Exclusion Criteria:
- • Endocarditis
About Kuopio University Hospital
Kuopio University Hospital is a leading academic medical center located in Finland, dedicated to advancing healthcare through innovative research and clinical trials. As a prominent sponsor of clinical studies, the hospital integrates cutting-edge scientific inquiry with patient-centered care, focusing on diverse therapeutic areas. With a commitment to enhancing treatment outcomes and improving patient quality of life, Kuopio University Hospital fosters collaboration among multidisciplinary teams, leveraging its robust infrastructure and expertise to drive medical progress and translate research findings into practice.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kuopio, , Finland
Patients applied
Trial Officials
Pasi K Lahtinen, MD
Principal Investigator
Kuopio University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials